ImmuneOnco Biopharmaceuticals (Shanghai) Inc Sustainability Reports
The company is a science-driven biotechnology firm dedicated to the development of innovative immuno-oncology therapies. It focuses on research and development pipelines that target both the innate and adaptive immune systems to treat cancer and autoimmune diseases.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
LEI: 25490040OVM0N5Z3GG60
FIGI: BBG00QKHV748
6 reports from 2023 to 2025
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc 2025 Annual Report
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc 2025 Environmental, Social and Governance Report
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc 2024 Annual Report
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc 2024 Environmental, Social and Governance Report
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc 2023 Annual Report